Idiopathic  ||| S:0 E:11 ||| FW
juxtafoveal  ||| S:11 E:23 ||| FW
retinal  ||| S:23 E:31 ||| FW
telangiectasis  ||| S:31 E:46 ||| FW
and  ||| S:46 E:50 ||| CC
retinal  ||| S:50 E:58 ||| JJ
macroaneurysm  ||| S:58 E:72 ||| NNS
treated  ||| S:72 E:80 ||| VBN
with  ||| S:80 E:85 ||| IN
indocyanine  ||| S:85 E:97 ||| JJ
green  ||| S:97 E:103 ||| JJ
dye-enhanced  ||| S:103 E:116 ||| JJ
photocoagulation  ||| S:116 E:133 ||| NNS
This  ||| S:133 E:138 ||| DT
case  ||| S:138 E:143 ||| NN
report  ||| S:143 E:150 ||| NN
presents  ||| S:150 E:159 ||| VBZ
the  ||| S:159 E:163 ||| DT
use  ||| S:163 E:167 ||| NN
of  ||| S:167 E:170 ||| IN
indocyanine  ||| S:170 E:182 ||| JJ
green  ||| S:182 E:188 ||| JJ
dye-enhanced  ||| S:188 E:201 ||| JJ
photocoagulation  ||| S:201 E:218 ||| NNS
( ||| S:218 E:219 ||| -LRB-
ICG-DEP ||| S:219 E:226 ||| NNP
)  ||| S:226 E:228 ||| -RRB-
for  ||| S:228 E:232 ||| IN
the  ||| S:232 E:236 ||| DT
treatment  ||| S:236 E:246 ||| NN
of  ||| S:246 E:249 ||| IN
idiopathic  ||| S:249 E:260 ||| FW
juxtafoveal  ||| S:260 E:272 ||| FW
retinal  ||| S:272 E:280 ||| FW
telangiectasis  ||| S:280 E:295 ||| FW
and  ||| S:295 E:299 ||| CC
a  ||| S:299 E:301 ||| DT
retinal  ||| S:301 E:309 ||| JJ
macroaneurysm ||| S:309 E:322 ||| NN
.  ||| S:322 E:324 ||| .
A  ||| S:324 E:326 ||| DT
35-year-old  ||| S:326 E:338 ||| JJ
male  ||| S:338 E:343 ||| NN
with  ||| S:343 E:348 ||| IN
20 ||| S:348 E:350 ||| CD
/ ||| S:350 E:351 ||| CD
20  ||| S:351 E:354 ||| CD
vision  ||| S:354 E:361 ||| NN
had  ||| S:361 E:365 ||| VBD
been  ||| S:365 E:370 ||| VBN
followed  ||| S:370 E:379 ||| VBN
for  ||| S:379 E:383 ||| IN
5  ||| S:383 E:385 ||| CD
years  ||| S:385 E:391 ||| NNS
for  ||| S:391 E:395 ||| IN
a  ||| S:395 E:397 ||| DT
retinal  ||| S:397 E:405 ||| JJ
macroaneurysm  ||| S:405 E:419 ||| NN
with  ||| S:419 E:424 ||| IN
retinal  ||| S:424 E:432 ||| JJ
telangiectasis  ||| S:432 E:447 ||| NN
outside  ||| S:447 E:455 ||| IN
the  ||| S:455 E:459 ||| DT
macular  ||| S:459 E:467 ||| JJ
area ||| S:467 E:471 ||| NN
.  ||| S:471 E:473 ||| .
He  ||| S:473 E:476 ||| PRP
then  ||| S:476 E:481 ||| RB
presented  ||| S:481 E:491 ||| VBN
with  ||| S:491 E:496 ||| IN
a  ||| S:496 E:498 ||| DT
recently  ||| S:498 E:507 ||| RB
decreased  ||| S:507 E:517 ||| VBN
vision  ||| S:517 E:524 ||| NN
in  ||| S:524 E:527 ||| IN
his  ||| S:527 E:531 ||| PRP$
right ||| S:531 E:536 ||| NN
.  ||| S:536 E:538 ||| .
He  ||| S:538 E:541 ||| PRP
had  ||| S:541 E:545 ||| VBD
macular  ||| S:545 E:553 ||| JJ
edema  ||| S:553 E:559 ||| NN
with  ||| S:559 E:564 ||| IN
a  ||| S:564 E:566 ||| DT
new  ||| S:566 E:570 ||| JJ
area  ||| S:570 E:575 ||| NN
of  ||| S:575 E:578 ||| IN
idiopathic  ||| S:578 E:589 ||| FW
juxtafoveal  ||| S:589 E:601 ||| FW
retinal  ||| S:601 E:609 ||| FW
telangiectasis ||| S:609 E:623 ||| FW
.  ||| S:623 E:625 ||| .
After  ||| S:625 E:631 ||| IN
4  ||| S:631 E:633 ||| CD
focal  ||| S:633 E:639 ||| JJ
argon  ||| S:639 E:645 ||| JJ
laser  ||| S:645 E:651 ||| NN
treatments ||| S:651 E:661 ||| NNS
,  ||| S:661 E:663 ||| ,
angiographic  ||| S:663 E:676 ||| JJ
closure  ||| S:676 E:684 ||| NN
of  ||| S:684 E:687 ||| IN
the  ||| S:687 E:691 ||| DT
lesions  ||| S:691 E:699 ||| NN
was  ||| S:699 E:703 ||| VBD
not  ||| S:703 E:707 ||| RB
obtained  ||| S:707 E:716 ||| VBN
and  ||| S:716 E:720 ||| CC
the  ||| S:720 E:724 ||| DT
retinal  ||| S:724 E:732 ||| JJ
edema  ||| S:732 E:738 ||| NN
remained ||| S:738 E:746 ||| VBD
.  ||| S:746 E:748 ||| .
After  ||| S:748 E:754 ||| IN
3  ||| S:754 E:756 ||| CD
sessions  ||| S:756 E:765 ||| NNS
of  ||| S:765 E:768 ||| IN
ICG-DEP ||| S:768 E:775 ||| NNP
,  ||| S:775 E:777 ||| ,
the  ||| S:777 E:781 ||| DT
lesions  ||| S:781 E:789 ||| NN
were  ||| S:789 E:794 ||| VBD
closed  ||| S:794 E:801 ||| VBN
and  ||| S:801 E:805 ||| CC
the  ||| S:805 E:809 ||| DT
edema  ||| S:809 E:815 ||| JJ
absorbed ||| S:815 E:823 ||| NN
.  ||| S:823 E:825 ||| .
The  ||| S:825 E:829 ||| DT
810  ||| S:829 E:833 ||| CD
nm  ||| S:833 E:836 ||| CD
infrared  ||| S:836 E:845 ||| JJ
laser  ||| S:845 E:851 ||| NN
with  ||| S:851 E:856 ||| IN
ICG-DEP  ||| S:856 E:864 ||| NNP
should  ||| S:864 E:871 ||| MD
be  ||| S:871 E:874 ||| VB
considered  ||| S:874 E:885 ||| VBN
for  ||| S:885 E:889 ||| IN
the  ||| S:889 E:893 ||| DT
treatment  ||| S:893 E:903 ||| NN
of  ||| S:903 E:906 ||| IN
idiopathic  ||| S:906 E:917 ||| FW
juxtafoveal  ||| S:917 E:929 ||| FW
retinal  ||| S:929 E:937 ||| FW
telangiectasis  ||| S:937 E:952 ||| FW
and  ||| S:952 E:956 ||| CC
retinal  ||| S:956 E:964 ||| JJ
macroaneurysms ||| S:964 E:978 ||| NN
.  ||| S:978 E:980 ||| .
In  ||| S:980 E:983 ||| IN
this  ||| S:983 E:988 ||| DT
case  ||| S:988 E:993 ||| NN
the  ||| S:993 E:997 ||| DT
procedure  ||| S:997 E:1007 ||| NN
appears  ||| S:1007 E:1015 ||| VBZ
to  ||| S:1015 E:1018 ||| TO
be  ||| S:1018 E:1021 ||| VB
safe  ||| S:1021 E:1026 ||| JJ
and  ||| S:1026 E:1030 ||| CC
well  ||| S:1030 E:1035 ||| RB
tolerated ||| S:1035 E:1044 ||| VBN
.  ||| S:1044 E:1046 ||| .
It  ||| S:1046 E:1049 ||| PRP
may  ||| S:1049 E:1053 ||| MD
allow  ||| S:1053 E:1059 ||| VB
for  ||| S:1059 E:1063 ||| IN
more  ||| S:1063 E:1068 ||| RBR
direct  ||| S:1068 E:1075 ||| JJ
energy  ||| S:1075 E:1082 ||| NN
absorption  ||| S:1082 E:1093 ||| NN
than  ||| S:1093 E:1098 ||| IN
that  ||| S:1098 E:1103 ||| DT
of  ||| S:1103 E:1106 ||| IN
the  ||| S:1106 E:1110 ||| DT
argon  ||| S:1110 E:1116 ||| JJ
laser  ||| S:1116 E:1122 ||| NN
to  ||| S:1122 E:1125 ||| TO
these  ||| S:1125 E:1131 ||| DT
types  ||| S:1131 E:1137 ||| NNS
of  ||| S:1137 E:1140 ||| IN
retinal  ||| S:1140 E:1148 ||| JJ
lesions  ||| S:1148 E:1156 ||| NNS
with  ||| S:1156 E:1161 ||| IN
better  ||| S:1161 E:1168 ||| JJR
tissue  ||| S:1168 E:1175 ||| NN
closure ||| S:1175 E:1182 ||| NN
.  ||| S:1182 E:1184 ||| .
